All In Biotech

Drug Trial Radar · NCT07893600

Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of Oral Recombinant Human Chymotrypsin Lyophilized Powder in Improving Mucosal Visualization Clarity During Gastroscopy

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Dec 22, 2026

Study completion Dec 22, 2026

Sponsor

Lead sponsor
Healthgen Biotechnology Corp.Industry
Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study was designed to evaluate efficacy and safety of OsrhCT before upper endoscopy on visibility of gastric mucosa. A total of 40 subjects (both male and female) are expected to be enrolled in this trial.

Conditions

  • Gastric Mucosal Lesion

Interventions

  • Recombinant Human Chymotrypsin(OsrhCT) 4000UDrug

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/bag, freeze-dried powder

  • Placebo for Recombinant Human Chymotrypsin(OsrhCT)Drug

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/bag, freeze-dried powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total visibility score (TVS) evaluated by blinded endoscopistsTime frame: Through study completion, up to 2 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.